|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 132.36 AUD | +1.30% |
|
+3.46% | -23.34% |
| 12:18pm | US FDA approves first mRNA flu shot from Moderna | RE |
| 31/07 | Australian shares log best month since February as rate-hike worries ease | RE |
Company Valuation: CSL Limited
Data adjusted to current consolidation scope
| Fiscal Period: June | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 97,314 | 89,299 | 89,052 | 95,184 | 76,024 | 44,719 | - | - |
| Change | - | -8.24% | -0.28% | 6.89% | -20.13% | -41.18% | - | - |
| Enterprise Value (EV) 1 | 101,307 | 88,520 | 99,731 | 105,710 | 85,005 | 53,434 | 52,695 | 52,042 |
| Change | - | -12.62% | 12.66% | 5.99% | -19.59% | -37.14% | -1.38% | -1.24% |
| P/E | 41x | 38.6x | 40.8x | 36.1x | 25.4x | -59.2x | 32.5x | 14.3x |
| PBR | 11.6x | 6.13x | 5.64x | 5.48x | 3.93x | 2.73x | 2.72x | 2.5x |
| PEG | - | -4.91x | -7.25x | 1.8x | 1.9x | 0x | -0x | 0x |
| Capitalization / Revenue | 9.44x | 8.45x | 6.69x | 6.43x | 4.89x | 2.91x | 2.87x | 2.76x |
| EV / Revenue | 9.83x | 8.38x | 7.49x | 7.14x | 5.46x | 3.47x | 3.38x | 3.22x |
| EV / EBITDA | 27.2x | 24.6x | 25.6x | 22.3x | 16.5x | 10.3x | 10.2x | 9.67x |
| EV / EBIT | 32.4x | 30.2x | 32.5x | 27.7x | 19x | 12x | 11.9x | 11.3x |
| EV / FCF | 41.8x | 57.1x | 72.6x | 55.2x | 29.1x | 19.4x | 17.6x | 18x |
| FCF Yield | 2.39% | 1.75% | 1.38% | 1.81% | 3.44% | 5.16% | 5.69% | 5.57% |
| Dividend per Share 2 | 2.22 | 2.22 | 2.36 | 2.64 | 2.92 | 2.857 | 2.925 | 3.089 |
| Rate of return | 1.04% | 1.2% | 1.28% | 1.34% | 1.86% | 3.1% | 3.17% | 3.35% |
| EPS 2 | 5.21 | 4.8 | 4.53 | 5.45 | 6.17 | -1.557 | 2.837 | 6.466 |
| Distribution rate | 42.6% | 46.3% | 52.1% | 48.4% | 47.3% | -184% | 103% | 47.8% |
| Net sales 1 | 10,310 | 10,562 | 13,310 | 14,800 | 15,558 | 15,380 | 15,589 | 16,173 |
| EBITDA 1 | 3,720 | 3,596 | 3,900 | 4,750 | 5,151 | 5,200 | 5,152 | 5,381 |
| EBIT 1 | 3,130 | 2,927 | 3,069 | 3,812 | 4,468 | 4,459 | 4,422 | 4,603 |
| Net income 1 | 2,375 | 2,255 | 2,194 | 2,642 | 3,002 | -966.7 | 1,185 | 3,090 |
| Net Debt 1 | 3,993 | -778.6 | 10,679 | 10,526 | 8,981 | 8,715 | 7,977 | 7,323 |
| Reference price 2 | 213.82 | 185.38 | 184.61 | 196.96 | 157.01 | 92.18 | 92.18 | 92.18 |
| Nbr of stocks (in thousands) | 455,126 | 481,706 | 482,372 | 483,253 | 484,212 | 478,912 | - | - |
| Announcement Date | 17/8/21 | 16/8/22 | 14/8/23 | 12/8/24 | 18/8/25 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -59.22x | 3.44x | 10.16x | 3.1% | 44.14B | |
| 18.15x | 4.14x | 9.73x | 0.51% | 76.75B | |
| 23.27x | 5.08x | 14.76x | 0.64% | 50.46B | |
| 36.31x | 12.41x | 23.62x | -.--% | 48.5B | |
| 37.6x | 3.42x | 12.82x | -.--% | 30.53B | |
| 53.46x | 3.37x | 26.12x | -.--% | 24.28B | |
| -6.56x | 8.93x | -5.76x | -.--% | 22.46B | |
| 68.17x | 6.51x | 43.28x | -.--% | 20.04B | |
| -36.51x | 17.55x | -48.02x | -.--% | 16.03B | |
| 23.1x | 4.97x | 12.95x | -.--% | 16.14B | |
| Average | 15.78x | 6.98x | 9.97x | 0.42% | 34.93B | |
| Weighted average by Cap. | 14.79x | 6.32x | 12.28x | 0.6% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- CSL Stock
- Valuation CSL Limited
Select your edition
All financial news and data tailored to specific country editions
